Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly

The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite being worth only $2.4 billion in 2022.Where should investors place their bets to gain some exposure to this hotter-than-hot trend? An investment in one of the established market leaders, like Eli Lilly (LLY 1.30%), could be sufficient -- but buying shares of an up-and-coming biotech like Viking Therapeutics (VKT ...